Search Results for:
-
ASCO Abstracts Shine Light on Cancer Immunotherapy
Roy S. Herbst, professor of medicine at Yale University Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven, summarized a Phase I expansion study of MPDL3280A, a human monoclonal antibody currently in development at Genentech Inc., a unit of Roche AG, of Basel, SwitzerlandBy Marie Powers | BioWorld Today | Thursday, May 16, 2013 -
Gradalis' FANG Phase II Peek: Strong Data in Ovarian Cancer
Speaking from the meeting, John Nemunaitis, Gradalis' chief medical officer and founder, said the full data from the Phase II trial, which is powered to enroll a total of about 60 patients, will be available in "eight or nine monthsBy Randy Osborne | BioWorld Today | Thursday, May 16, 2013 -
Pearl's LAMA/LABA Combo Inhaler Enters Phase III Trial
Colin Reisner, chief medical officer for Pearl, told BioWorld Today that the company completed its dose-ranging studies at the end of 2012 and has had discussions with the European Medicines Agency, Health Canada and the FDA, including an end-of-Phase-II meeting with the FDABy Catherine Shaffer | BioWorld Today | Wednesday, May 15, 2013 -
Ovarian Trial 'MEKs' Big Year: Array Rolls Out Five Phase IIIs
Michael Needle, chief medical officer of Array, told BioWorld Today that diagnosing is fairly straightforward with LGSOC, with its "relatively mature-looking cells, as opposed to the wildly anaplastic, ugly malignant cellsBy Randy Osborne | BioWorld Today | Wednesday, May 8, 2013 -
Appointments and Advancements
Vanda Pharmaceuticals Inc., of Washington, named Paolo Baroldi senior vice president and chief medical officerBioWorld Today | Tuesday, May 7, 2013 -
FDA Gives its Nod to Procysbi; Raptor Ascends
In a conference call late Monday afternoon, Patrice Rioux, Raptor's chief medical officer, said 40 patients who participated in Procysbi's Phase III trial have remained on the open-label extension – some for up to two years – with no unexpected severe adverse eventsBy Marie Powers | BioWorld Today | Wednesday, May 1, 2013 -
Personalized Medicine Market Reaching Its Adolescence
The pace of innovation in personalized medicine diagnostics is often slowed by the demands of clinical utility in FDA submissions," Tadd Lazarus, chief medical officer of Qiagen's Global Molecular Diagnostics Group, explained to BioWorld TodayBy Jonathan Goldstein | BioWorld Today | Monday, April 29, 2013 -
Combo Treatment Answer to Cancer, but Challenges Remain
And, of course, there are assays, but even if an assay "is extremely precise, the tumor is heterogenous," said Mohammad Azab, chief medical officer of fragment-based drug discovery firm Astex Pharmaceuticals Inc...The Needham, Mass.-based firm has generated buzz with its lead program, rindopepimut, an immunotherapy targeting epidermal growth factor variant III, in pivotal testing in glioblastoma multiforme, but the company's goal is really to combine several of its internal programs, said Tom DavisBy Jennifer Boggs | BioWorld Today | Tuesday, April 23, 2013 -
Appointments and Advancements
BIND Therapeutics Inc., of Cambridge, Mass., named Gregory I. Berk chief medical officerBioWorld Today | Tuesday, April 16, 2013 -
Other News To Note
In the same 8-K filing disclosing the collaboration amendment, Affymax also reported the departure of directors and certain officers, including executive officers Anne-Marie Duliege, chief medical officer, and Karin Walker, vice president of finance and chief accounting officerBioWorld Today | Friday, April 12, 2013 -
Vernal Aquinox: Series C Gets $18M to Finish Phase II Trials
The company also disclosed the appointment of Stephen Shrewsbury as senior vice president of clinical development and chief medical officer (CMOBy Randy Osborne | BioWorld Today | Thursday, April 4, 2013 -
Appointments and Advancements
Biocartis SA, of Lausanne, Switzerland, named Stefan Scherer chief medical officer...Cell Medica Ltd., of London, appointed Kurt Gunter chief medical officer, Jeff Hammel chief financial officer and Ross Durland senior vice president development with global responsibility for product developmentBioWorld Today | Monday, April 1, 2013 -
Safinamide Hits Endpoints in Two Parkinson's Phase III Trials
Ravi Anand, chief medical officer at Milan, Italy-based Newron told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, March 20, 2013 -
Safinamide Hits Endpoints in Two Parkinson's Phase III Trials
Ravi Anand, chief medical officer at Milan, Italy-based Newron told BioWorld TodayBy Cormac Sheridan | BioWorld Today | Wednesday, March 20, 2013 -
Planning for Global Expansion, Cell Medica Recruits New CMO
has attracted Kurt Gunter, a leader of cell therapy in the U.S., to be its chief medical officer, in one of five senior appointments that will see the London-based company scaling up to a global operationBy Nuala Moran | BioWorld International | Wednesday, March 13, 2013 -
Appointments and Advancements
Cytori Therapeutics Inc., of San Diego, named Steven Kesten executive vice president and chief medical officer...Kala Pharmaceuticals Inc., of Waltham, Mass., named Kim Brazzell chief medical officerBioWorld Today | Thursday, March 7, 2013 -
Appointments and Advancements
Repros Therapeutics Inc., of The Woodlands, Texas, appointed Joachim F. Wernicke chief medical officerBioWorld Today | Tuesday, March 5, 2013 -
Panel Gives Thumbs-Down to Depomed's Hot Flash Drug
Chief Medical Officer Michael Sweeney pointed to improvements in the Patient Global Impression of Change scores and improvement in insomnia due to VMSBy Jennifer Boggs | BioWorld Today | Tuesday, March 5, 2013 -
EnVivo Boldly Launches Solo Phase III in Schizophrenia
The 26-week multinational trials are designed to enroll approximately 700 patients each in more than 100 centers, according to Dana Hilt, EnVivo's senior vice president of clinical development and chief medical officer, with both evaluating two doses of EVP-6124 compared to placeboBy Marie Powers | BioWorld Today | Friday, March 1, 2013 -
Affymax Crashes on Omontys Recall, Hypersensitivity Data
But the postmarketing rate was "vastly different in terms of seriousness," noted Anne-Marie Duliege, chief medical officerBy Jennifer Boggs | BioWorld Today | Tuesday, February 26, 2013
Category
Current Filters
- xchief medical
Related Keywords
Categories
- x BioWorld Today (756)
- x BioWorld International (90)
- x BioWorld Insight (53)
- x Bio Perspectives (23)
- x BioWorld Genomics Review (16)
- x Executive Compensation Report (10)
- x State of the Industry Report (3)
- x Biotech Innovations (2)
- x Top 25 Drug Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.